You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKesson
Medtronic
Mallinckrodt
Dow

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Litigation Details for Novartis Pharmaceuticals Corporation v. Roxane Laboratories Inc. (D. Del. 2014)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Roxane Laboratories Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-09-16
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties BOEHRINGER INGELHEIM ROXANE INC.; NOVARTIS AG; NOVARTIS PHARMACEUTICALS CORPORATION; ROXANE LABORATORIES INC.
Patents 6,004,973; 6,239,124; 6,455,518
Attorneys Bindu Ann George Palapura; Christina Schwarz; Christopher E. Loh; Corinne E. Atton; Daniel M. Silver; David Ellis Moore; Keith A. Zullow; Laura Fishwick; Marta E. Gross; Michael B. Cottler; Naomi l. Birbach; Nicholas N. Kallas; Richard L. Horwitz; Stephanie E. O'Byrne; Steven J. Bernstein; Timothy J. Doyle
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Roxane Laboratories Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Novartis Pharmaceuticals Corporation v. Roxane Laboratories Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-09-16 1 United States Letters Patent No. 6,004,973 (“the ‘973 patent”). The ‘973 patent was duly and legally …United States Letters Patent No. 5,665,772 (“the ‘772 patent”). The ‘772 patent was duly and legally …United States Letters Patent No. 6,239,124 (“the ‘124 patent”). The ‘124 patent was duly and legally …United States Letters Patent No. 6,455,518 (“the ‘518 patent”). The ‘518 patent was duly and legally …772, ‘973, ‘124, and ‘518 patents was an act of infringement of those patents. 32. External link to document
2016-09-26 169 Of U.S. Patent No. 5,665,772 For Obviousness And The Invalidity Of U.S. Patent Nos. 6,239,124 and 6,455…For Obviousness and For Obviousness-Type Double Patenting, by Roxane Laboratories Inc.. (O'Byrne, Stephanie…16 September 2014 1:14-cv-01196 830 Patent None District Court, D. Delaware External link to document
2016-10-17 177 Brief Regarding Noninfringement of U.S. Patent Nos. 6,239,124 and 6,455,518, by Roxane Laboratories Inc…16 September 2014 1:14-cv-01196 830 Patent None District Court, D. Delaware External link to document
2016-10-25 182 Obviousness of U.S. Patent No. 5,665,772 and Invalidity of U.S. Patent Nos. 6,239,124 and 6,455,518, by …16 September 2014 1:14-cv-01196 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Mallinckrodt
Medtronic
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.